Search

Your search keyword '"Creutzberg, Carien L"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Creutzberg, Carien L" Remove constraint Author: "Creutzberg, Carien L" Database Complementary Index Remove constraint Database: Complementary Index
46 results on '"Creutzberg, Carien L"'

Search Results

1. Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial.

2. Sexual health—a topic for cancer patients receiving oncological treatment with palliative intent.

3. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.

4. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

5. MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma.

6. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.

7. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.

10. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.

11. A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial.

12. A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial.

14. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.

15. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

16. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.

17. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

19. Differences in health care professionals' and cancer patients' views on sexual health issues.

20. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

21. Phase 1–3 of the cross‐cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ‐22.

22. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

23. Blinded histopathological characterisation of POLE exonuclease domain -mutant endometrial cancers: sheep in wolf's clothing.

24. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.

25. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial.

32. Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy.

33. Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors--results from a Dutch population-based study.

34. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.

35. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System.

36. Sweat production in children's feet.

38. Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study.

39. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.

40. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.

41. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

42. ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial.

43. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

44. Prognostic significance of POLE proofreading mutations in endometrial cancer.

45. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer.

Catalog

Books, media, physical & digital resources